search
Back to results

The Clinical Evaluation of Implantable Pump System For Safety And Delivery Accuracy In Patients Requiring Intrathecal Administration Of Morphine Sulfate For Chronic Pain

Primary Purpose

Cancers, Chronic Pain

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Implantation of Morphine Sulfate delivering programmable pump
Sponsored by
Medallion Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cancers focused on measuring Chronic pain, Morphine Sufate, Intrathecal, Implantable drug delivery pumps

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Subject must be at least 21 years of age.
  2. Subject must have experienced chronic pain for at least 6 months.
  3. Subject must not presently be on intrathecal therapy but must be considered a candidate for intrathecal analgesia by his pain specialist; or, a subject already on intrathecal therapy must be in need of a replacement intrathecal pump and catheter.
  4. Subject must be capable of giving informed consent.
  5. Subjects who agree to sign a Pain Treatment Agreement (Narcotic Contract) limiting narcotic prescriptions to the study physician.
  6. Subjects who agree to periodic drug testing.
  7. Subject must be capable and willing to follow all study-related procedures, including returning for monthly refills.
  8. Subject must be cognitively intact and, in the opinion of the Investigator, capable of using the Patient Remote.
  9. Subject who is not already successfully treated with intrathecal analgesic therapy must be responsive to a trial of intrathecal or epidural morphine.
  10. Female subjects of child-bearing potential must agree to use a medically acceptable and effective double-barrier method of birth control.
  11. Documented failure to respond to less invasive methods of pain control (such as physical or behavioral modifications).
  12. Ineffective pain control with single or multiple systemic analgesic treatments (oral, rectal, IV or transdermal) or had intolerable side effects.
  13. Cancer pain requiring strong opioids or non-malignant pain with average Visual Analog Scale (VAS) score of ≥ 4/10.
  14. Subjects who can receive an MRI.
  15. Subjects must be able to hear and respond to audible alarms or agree to have a support person available who is able to hear and respond to audible alarms.

Exclusion Criteria:

  1. Subject is a female who is pregnant or is planning a pregnancy.
  2. Subject is a nursing mother.
  3. Subject has at the site chosen for implantation a skin condition that would prevent the implantation procedure.
  4. Subject has participated in an investigational drug or device trial within 4 weeks prior to enrollment.
  5. Subject has any known or suspected allergy to morphine or to the materials of the infusion pump or intrathecal catheter.
  6. Subject shows signs of active, systemic infection.
  7. Subject has a known central nervous system contraindication to intrathecal therapy, including but not limited to severe spinal canal stenosis or spinal cord compression.
  8. Subject has a body size that is insufficient to accept the bulk and weight of the pump.
  9. Subject is allergic to morphine sulfate, or for whom morphine sulfate is contraindicated.
  10. Subject has a condition requiring diathermy procedures.
  11. Subject has a life expectancy of less than 9 months.
  12. Subject cannot independently comprehend and participate in the required assessments, including responding to the QOL, BPI, ODI and PGIC measurement tools.
  13. Subject is not considered to be medically or psychologically appropriate for pump implantation.
  14. Subject has a urine drug screen result which indicates the use of prescription drugs or controlled substances not on the order of a physician.
  15. Subjects with an ASA Physical Status >IV.
  16. Subjects with a history of spinal instability, or grade II spondylolisthesis or greater.
  17. Previously implanted subjects with spinal MRI findings of inflammatory mass prior to the implantation procedures.
  18. Subjects who are unable or unwilling to return to all of the required follow-up visits.
  19. Subjects who are unwilling to sign the informed consent.
  20. Subjects who are exposed to high-current industrial equipment (i.e. electricians or electrical engineers) or regularly exposed to MRI equipment (i.e. MRI technicians, MRI engineers and MRI clinicians).
  21. Subjects with active implanted devices such as pacemakers, defibrillators, cochlear implants and neurostimulators or other medical device use that can interfere with the function of the implanted intrathecal pump.

Sites / Locations

  • Center for Pain & Supportive Care
  • Coastal Pain Research
  • University of California San Diego
  • Neurovations
  • Millenium Pain Center
  • Global Scientific Innovations, LLC
  • Center for Pain Management
  • The Center for Clinical Research
  • Pain Research of Oregon

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Subjects with Implantable pump

Arm Description

Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo study device implantation .

Outcomes

Primary Outcome Measures

• Mean medication delivery accuracy.
Medication delivery accuracy will be evaluated at each of six (6) refills.

Secondary Outcome Measures

• Tabulation of Adverse Events
Concomitant Medications, Physical and Neurological Exam, Inflammatory Masses, Vital Signs, Incidence of Inflammatory Masses, Summary of COWS
Tabulation of Concomitant Medications, Tabulation of Physical and Neurological, Exam, Summary of Vital Signs, Incidence of Inflammatory Masses, Summary of COWS

Full Information

First Posted
August 18, 2010
Last Updated
April 20, 2017
Sponsor
Medallion Therapeutics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01185470
Brief Title
The Clinical Evaluation of Implantable Pump System For Safety And Delivery Accuracy In Patients Requiring Intrathecal Administration Of Morphine Sulfate For Chronic Pain
Official Title
THE CLINICAL EVALUATION OF IMPLANTABLE PUMP SYSTEM FOR SAFETY AND DELIVERY ACCURACY IN PATIENTS REQUIRING INTRATHECAL ADMINISTRATION OF MORPHINE SULFATE FOR CHRONIC PAIN
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
February 2011 (undefined)
Primary Completion Date
January 2015 (Actual)
Study Completion Date
July 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medallion Therapeutics, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
• The objectives of this study are to confirm the medication delivery accuracy of the Infusion System, LLC Implantable Drug Delivery System (IDDS) with Patient Controlled Analgesia for intrathecal delivery of morphine sulfate for pain control, and to determine the safety profile of the system with PCA for intrathecal delivery of morphine sulfate for pain control.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancers, Chronic Pain
Keywords
Chronic pain, Morphine Sufate, Intrathecal, Implantable drug delivery pumps

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
75 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Subjects with Implantable pump
Arm Type
Experimental
Arm Description
Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo study device implantation .
Intervention Type
Device
Intervention Name(s)
Implantation of Morphine Sulfate delivering programmable pump
Intervention Description
Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo implantation of pump for intrathecal delivery of Morphine Sulfate.
Primary Outcome Measure Information:
Title
• Mean medication delivery accuracy.
Description
Medication delivery accuracy will be evaluated at each of six (6) refills.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
• Tabulation of Adverse Events
Time Frame
12 months
Title
Concomitant Medications, Physical and Neurological Exam, Inflammatory Masses, Vital Signs, Incidence of Inflammatory Masses, Summary of COWS
Description
Tabulation of Concomitant Medications, Tabulation of Physical and Neurological, Exam, Summary of Vital Signs, Incidence of Inflammatory Masses, Summary of COWS
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject must be at least 21 years of age. Subject must have experienced chronic pain for at least 6 months. Subject must not presently be on intrathecal therapy but must be considered a candidate for intrathecal analgesia by his pain specialist; or, a subject already on intrathecal therapy must be in need of a replacement intrathecal pump and catheter. Subject must be capable of giving informed consent. Subjects who agree to sign a Pain Treatment Agreement (Narcotic Contract) limiting narcotic prescriptions to the study physician. Subjects who agree to periodic drug testing. Subject must be capable and willing to follow all study-related procedures, including returning for monthly refills. Subject must be cognitively intact and, in the opinion of the Investigator, capable of using the Patient Remote. Subject who is not already successfully treated with intrathecal analgesic therapy must be responsive to a trial of intrathecal or epidural morphine. Female subjects of child-bearing potential must agree to use a medically acceptable and effective double-barrier method of birth control. Documented failure to respond to less invasive methods of pain control (such as physical or behavioral modifications). Ineffective pain control with single or multiple systemic analgesic treatments (oral, rectal, IV or transdermal) or had intolerable side effects. Cancer pain requiring strong opioids or non-malignant pain with average Visual Analog Scale (VAS) score of ≥ 4/10. Subjects who can receive an MRI. Subjects must be able to hear and respond to audible alarms or agree to have a support person available who is able to hear and respond to audible alarms. Exclusion Criteria: Subject is a female who is pregnant or is planning a pregnancy. Subject is a nursing mother. Subject has at the site chosen for implantation a skin condition that would prevent the implantation procedure. Subject has participated in an investigational drug or device trial within 4 weeks prior to enrollment. Subject has any known or suspected allergy to morphine or to the materials of the infusion pump or intrathecal catheter. Subject shows signs of active, systemic infection. Subject has a known central nervous system contraindication to intrathecal therapy, including but not limited to severe spinal canal stenosis or spinal cord compression. Subject has a body size that is insufficient to accept the bulk and weight of the pump. Subject is allergic to morphine sulfate, or for whom morphine sulfate is contraindicated. Subject has a condition requiring diathermy procedures. Subject has a life expectancy of less than 9 months. Subject cannot independently comprehend and participate in the required assessments, including responding to the QOL, BPI, ODI and PGIC measurement tools. Subject is not considered to be medically or psychologically appropriate for pump implantation. Subject has a urine drug screen result which indicates the use of prescription drugs or controlled substances not on the order of a physician. Subjects with an ASA Physical Status >IV. Subjects with a history of spinal instability, or grade II spondylolisthesis or greater. Previously implanted subjects with spinal MRI findings of inflammatory mass prior to the implantation procedures. Subjects who are unable or unwilling to return to all of the required follow-up visits. Subjects who are unwilling to sign the informed consent. Subjects who are exposed to high-current industrial equipment (i.e. electricians or electrical engineers) or regularly exposed to MRI equipment (i.e. MRI technicians, MRI engineers and MRI clinicians). Subjects with active implanted devices such as pacemakers, defibrillators, cochlear implants and neurostimulators or other medical device use that can interfere with the function of the implanted intrathecal pump.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard Rauck, MD
Organizational Affiliation
The Center for Clinical Research
Official's Role
Principal Investigator
Facility Information:
Facility Name
Center for Pain & Supportive Care
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85258
Country
United States
Facility Name
Coastal Pain Research
City
Carlsbad
State/Province
California
ZIP/Postal Code
92009
Country
United States
Facility Name
University of California San Diego
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
Facility Name
Neurovations
City
Napa
State/Province
California
ZIP/Postal Code
94558
Country
United States
Facility Name
Millenium Pain Center
City
Bloomington
State/Province
Illinois
ZIP/Postal Code
61701
Country
United States
Facility Name
Global Scientific Innovations, LLC
City
Evansville
State/Province
Indiana
ZIP/Postal Code
47714
Country
United States
Facility Name
Center for Pain Management
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63109
Country
United States
Facility Name
The Center for Clinical Research
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27103
Country
United States
Facility Name
Pain Research of Oregon
City
Eugene
State/Province
Oregon
ZIP/Postal Code
97401
Country
United States

12. IPD Sharing Statement

Learn more about this trial

The Clinical Evaluation of Implantable Pump System For Safety And Delivery Accuracy In Patients Requiring Intrathecal Administration Of Morphine Sulfate For Chronic Pain

We'll reach out to this number within 24 hrs